Results 151 to 160 of about 2,247 (204)

Therapeutic approach to difficult-to-treat multidrug-resistant enterococcal infections. [PDF]

Antimicrob Agents Chemother
Turner AM, Kinsella P, Miller WR, Carter GP, Tran TT, Howden BP, Arias CA.   +6 more
europepmc   +1 more source

Reply to White and Siegrist, "Multi-drug-resistant enterococcal infections: duration of combination therapy and OPAT challenges". [PDF]

Antimicrob Agents Chemother
Arias CA, Tran TT, Kinsella P, Howden BP, Miller WR.   +4 more
europepmc   +1 more source

A strategy to re-sensitise drug-resistant Gram-positive bacteria to oxazolidinone-class antibiotics. [PDF]

EBioMedicine
Zhang Q, Yang Y, Yang Y, Shang J, Su S, Gao P, Li XX, Liu Z, Kao RY, Ko BC, Thompson B, Zhao Q.   +11 more
europepmc   +1 more source

Effect of antibiotics on Kupffer cell immunometabolism relative to intracellular killing of <i>S. aureus</i> using NAD(P)H fluorescence lifetime imaging. [PDF]

mBio
Beadell B, Wong-Beringer A.
europepmc   +1 more source

Positional isomerization of pyridine through nitrogen transposition. [PDF]

Nature
Choi W, Ju H, Park J, Hong S.
europepmc   +1 more source

Anaerobic bacteria: a neglected reservoir of mobile oxazolidinone resistance genes. [PDF]

Gut Microbes
Liu S, Xie S, Song Y, Li R, Brenciani A, Schwarz S, Zhang W, Zhu Y.   +7 more
europepmc   +1 more source

Safety and Tolerability of More than Six Days of Tedizolid Treatment.

Antimicrobial Agents and Chemotherapy, 2020
Tedizolid has demonstrated its efficacy and safety in clinical trials; however, data concerning its tolerability in long-term treatments are scarce.
Jose R Yuste, Miguel Salavert Lleti, Genis Castells-Lao   +2 more
exaly   +2 more sources

Tedizolid Phosphate: a Next-Generation Oxazolidinone [PDF]

Infectious Diseases and Therapy, 2015
Treatment of multidrug-resistant Gram-positive infections continues to challenge clinicians as the emergence of new resistance mechanisms outpaces introduction of novel antimicrobial agents. Tedizolid phosphate is a next-generation oxazolidinone with activity against both methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus
Jeffrey M Rybak
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

A closer inspection of tedizolid

The Lancet Infectious Diseases, 2015
I read the Article by Gregory Moran and colleagues, who used intention to treat (ITT) analysis of a noninferiority trial, with great interest. ITT is widely accepted as the appropriate analysis for randomised controlled trials. However, this recognition is based on assumptions of trial design. Superiority trials (ie, the attempt to prove treatment A is
openaire   +4 more sources